CAS 96829-58-2|Orlistat
| Common Name | Orlistat | ||
|---|---|---|---|
| CAS Number | 96829-58-2 | Molecular Weight | 495.735 |
| Density | 1.0±0.1 g/cm3 | Boiling Point | 615.9±30.0 °C at 760 mmHg |
| Molecular Formula | C29H53NO5 | Melting Point | <50ºC |
| MSDS | ChineseUSA | Flash Point | 326.3±24.6 °C |
Names
| Name | [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate |
|---|---|
| Synonym | More Synonyms |
Orlistat BiologicalActivity
| Description | Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats. |
|---|---|
| Related Catalog | Signaling Pathways >>Metabolic Enzyme/Protease >>Fatty Acid Synthase (FAS)Research Areas >>Metabolic Disease |
| References | [1]. Zhi J, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995 Nov;35(11):1103-8. [2]. Padwal R, et al. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;(3):CD004094. [3]. Zhang E, et al. Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis. Nutrients. 2018 Mar 15;10(3). pii: E353. |
Chemical & Physical Properties
| Density | 1.0±0.1 g/cm3 |
|---|---|
| Boiling Point | 615.9±30.0 °C at 760 mmHg |
| Melting Point | <50ºC |
| Molecular Formula | C29H53NO5 |
| Molecular Weight | 495.735 |
| Flash Point | 326.3±24.6 °C |
| Exact Mass | 495.392365 |
| PSA | 81.70000 |
| LogP | 8.94 |
| Appearance of Characters | solid | white |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.470 |
| InChIKey | AHLBNYSZXLDEJQ-FWEHEUNISA-N |
| SMILES | CCCCCCCCCCCC(CC1OC(=O)C1CCCCCC)OC(=O)C(CC(C)C)NC=O |
| Storage condition | 2-8°C |
| Water Solubility | DMSO: 19 mg/mL |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | OH3167600 |
Articles25
More Articles| Orlistat and calcium oxalate crystalluria: an association that needs consideration. Ren. Fail. 32(8) , 1019-21, (2010) Obesity is currently an epidemic across the globe. Obese patients unable to achieve significant weight loss with lifestyle changes alone may require drug therapy. Clinical trials have shown that orlis... | |
| Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation. J. La. State Med. Soc. 165(5) , 283-5, (2013) We present the case of a 61-year-old Caucasian male veteran who had been on orlistat (120mg dosing) for four years, and had changed to the over-the-counter (OTC) form, Alli (orlistat 60mg), about thre... | |
| Mechanisms of cholesterol and saturated fatty acid lowering by Quillaja saponaria extract, studied by in vitro digestion model. Food Funct. 6 , 1319-30, (2015) Quillaja saponin extracts are known to reduce plasma cholesterol levels in humans. Here we study the mechanism of this effect with Quillaja Dry saponin extract (QD). In vitro model of triglyceride lip... |
Synonyms
| [2S-[2a(R*),3b]]-N-Formyl-L-leucine 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester |
| (−)-Tetrahydrolipstatin |
| N-Formyl-L-leucine ester with (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]-2-oxetanone |
| (2S)-1-[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]-2-tridecanyl N-formyl-L-leucinate |
| Tetrahydrolipstatin |
| MFCD05662360 |
| (2S)-1-[(2S,3S)-3-Hexyl-4-oxooxetan-2-yl]tridecan-2-yl N-formyl-L-leucinate |
| Alli |
| (1S)-1-{[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]methyl}dodecyl N-formyl-L-leucinate |
| Orlistat |
| (1S)-1-{[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]methyl}dodecyl (2S)-2-(formylamino)-4-methylpentanoate |
| Orlipastat |
| Orlipastatum |
| L-Leucine, N-formyl-, (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester |
| Xenical |
| (-)-Tetrahydrolipstatin |
| THLP |
